ResearcherAmsterdam University Medical CentersActive in the last 2 years
Geng Xu
Matched on ORCID iD 0000-0002-4597-8729; OpenAlex author ID A5101820162. Sources: OpenAlex.
Their work
- Papers
- 9 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2022: 1 paper · 2023: 1 paper · 2024: 3 papers · 2025: 4 papers
Papers 9
- Novel Pyrazolo [1,5-a]-1,3,5-Triazine Derivatives as CDK7 Inhibitors: Synthesis and Biological Insights in Pancreatic Ductal Adenocarcinoma Models. Co-author DOI 10.1002/cmdc.202500448↗
- Corrigendum to "Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promising anticancer activity in pancreatic c… Co-author DOI 10.1016/j.bioorg.2024.107995↗
- Navigating the paradox of senescence and chemoresistance in pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2025.06.007↗
- Role of Oral Bacteria in Mediating Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.3390/biom15071018↗
- Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promising anticancer activity in pancreatic cancer models. Co-author DOI 10.1016/j.bioorg.2024.107959↗
- Exploring the therapeutic potential of a novel series of imidazothiadiazoles targeting focal adhesion kinase (FAK) for pancreatic cancer treatment: synthesis, … Co-author DOI 10.1080/1061186x.2024.2385557↗
- Pharmacological mechanisms underlying the interaction of the nucleoside analogue gemcitabine with the c-MET inhibitor tivantinib in pancreatic cancer. First author DOI 10.1080/15257770.2024.2319215↗
- 1,3,4-Oxadiazole and 1,3,4-Thiadiazole Nortopsentin Derivatives against Pancreatic Ductal Adenocarcinoma: Synthesis, Cytotoxic Activity, and Inhibition of CDK1. Co-author DOI 10.3390/md21070412↗
- Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance. Co-author DOI 10.1016/j.drup.2022.100864↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Elisa Giovannetti · 9 shared papers, 2022–2025 · strength 2.04
- Paper Pharmacological mechanisms underlying the interaction of the nucleoside analogue gemcitabine with the c-MET inhibitor t… DOI 10.1080/15257770.2024.2319215↗
- Paper Corrigendum to "Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promi… DOI 10.1016/j.bioorg.2024.107995↗
- Paper Navigating the paradox of senescence and chemoresistance in pancreatic cancer. DOI 10.1016/j.semcancer.2025.06.007↗
- Daniela Carbone · 5 shared papers, 2023–2025 · strength 1.09
- Paper Corrigendum to "Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promi… DOI 10.1016/j.bioorg.2024.107995↗
- Paper Novel Pyrazolo [1,5-a]-1,3,5-Triazine Derivatives as CDK7 Inhibitors: Synthesis and Biological Insights in Pancreatic D… DOI 10.1002/cmdc.202500448↗
- Paper Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promising anticancer … DOI 10.1016/j.bioorg.2024.107959↗
- Stella Cascioferro · 5 shared papers, 2023–2025 · strength 1.09
- Paper Corrigendum to "Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promi… DOI 10.1016/j.bioorg.2024.107995↗
- Paper Novel Pyrazolo [1,5-a]-1,3,5-Triazine Derivatives as CDK7 Inhibitors: Synthesis and Biological Insights in Pancreatic D… DOI 10.1002/cmdc.202500448↗
- Paper Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promising anticancer … DOI 10.1016/j.bioorg.2024.107959↗
- Camilla Pecoraro · 5 shared papers, 2023–2025 · strength 1.09
- Paper Corrigendum to "Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promi… DOI 10.1016/j.bioorg.2024.107995↗
- Paper Novel Pyrazolo [1,5-a]-1,3,5-Triazine Derivatives as CDK7 Inhibitors: Synthesis and Biological Insights in Pancreatic D… DOI 10.1002/cmdc.202500448↗
- Paper Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promising anticancer … DOI 10.1016/j.bioorg.2024.107959↗
- Barbara Parrino · 5 shared papers, 2023–2025 · strength 1.09
- Paper Corrigendum to "Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promi… DOI 10.1016/j.bioorg.2024.107995↗
- Paper Novel Pyrazolo [1,5-a]-1,3,5-Triazine Derivatives as CDK7 Inhibitors: Synthesis and Biological Insights in Pancreatic D… DOI 10.1002/cmdc.202500448↗
- Paper Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promising anticancer … DOI 10.1016/j.bioorg.2024.107959↗
- Patrizia Diana · 5 shared papers, 2023–2025 · strength 1.09
- Paper Corrigendum to "Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promi… DOI 10.1016/j.bioorg.2024.107995↗
- Paper Novel Pyrazolo [1,5-a]-1,3,5-Triazine Derivatives as CDK7 Inhibitors: Synthesis and Biological Insights in Pancreatic D… DOI 10.1002/cmdc.202500448↗
- Paper Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promising anticancer … DOI 10.1016/j.bioorg.2024.107959↗
- Juan Deng · 3 shared papers, 2024–2025 · strength 0.73
- Paper Corrigendum to "Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promi… DOI 10.1016/j.bioorg.2024.107995↗
- Paper Navigating the paradox of senescence and chemoresistance in pancreatic cancer. DOI 10.1016/j.semcancer.2025.06.007↗
- Paper Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promising anticancer … DOI 10.1016/j.bioorg.2024.107959↗
- Fabio Scianò · 3 shared papers, 2024–2025 · strength 0.67
- Paper Corrigendum to "Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promi… DOI 10.1016/j.bioorg.2024.107995↗
- Paper Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promising anticancer … DOI 10.1016/j.bioorg.2024.107959↗
- Paper Exploring the therapeutic potential of a novel series of imidazothiadiazoles targeting focal adhesion kinase (FAK) for … DOI 10.1080/1061186x.2024.2385557↗
- Godefridus J. Peters · 2 shared papers, 2024–2025 · strength 0.52
- Paper Pharmacological mechanisms underlying the interaction of the nucleoside analogue gemcitabine with the c-MET inhibitor t… DOI 10.1080/15257770.2024.2319215↗
- Paper Novel Pyrazolo [1,5-a]-1,3,5-Triazine Derivatives as CDK7 Inhibitors: Synthesis and Biological Insights in Pancreatic D… DOI 10.1002/cmdc.202500448↗
- Luca Morelli · 2 shared papers, 2025 · strength 0.51
- Dongmei Deng · 2 shared papers, 2022–2025 · strength 0.41
- Mahrou Vahabi · 1 shared paper, 2024 · strength 0.28
- Amir Avan · 1 shared paper, 2024 · strength 0.28
- Amal Jeiroshi · 1 shared paper, 2025 · strength 0.26
- Annalisa Comandatore · 1 shared paper, 2025 · strength 0.26
- Ingrid Garajová · 1 shared paper, 2025 · strength 0.26
- Giulia Lencioni · 1 shared paper, 2025 · strength 0.26
- Cecilia Bergonzini · 1 shared paper, 2024 · strength 0.20
- Macarena Perán · 1 shared paper, 2022 · strength 0.16
- Mjriam Capula · 1 shared paper, 2022 · strength 0.16
- Alessandro Gregori · 1 shared paper, 2022 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.